We read with great interest the article of Penso et al investigating whether IL17-inhibitors (IL17i) initiation is related to the greater risk of inflammatory bowel disease (IBD) in patients with psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) [1]. However, some points need to be discussed.

中文翻译：

---

银屑病、银屑病关节炎和强直性脊柱炎患者使用白细胞介素 17 抑制剂的炎症性肠病风险

我们非常感兴趣地阅读了 Penso等人的文章，该文章调查了 IL17 抑制剂 (IL17i) 的启动是否与银屑病 (PsO)、银屑病关节炎 (PsA) 和强直性脊柱炎患者的炎症性肠病 (IBD) 风险增加有关。如）[1]。但是，有些问题需要讨论。